RxDoctor Payments Data

Elizabeth Abell, MD

Infectious Disease · Spartanburg, SCNPI 1083623805

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,788 of the $2,136 with a category attached, or 83.7%. It is spread thinly across 15 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $614 and has fallen 64.6% since, to $218 in 2025.

$2,136in general payments, 2019–2025

Across 84 payments — averaging $25.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$376
  • Insmed, Inc.$371
  • Astellas Pharma US Inc$247
  • Merck$207
  • Zimvie Inc.$171
  • Paratek Pharmaceuticals, Inc.$155
  • plus $610 from 9 others

What the payments were for

  • Food & beverage$1,78884%
  • Education$34816%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,136 in reported general payments places this provider in the 65th percentile of 102 infectious disease providers in South Carolina.

See all infectious disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$39,444
Medicare patients
219
Services billed
392

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ArikayceAmikacin Liposomal/Neb.Accessr18$279,778
BiktarvyBictegrav/Emtricit/Tenofov Ala42$160,175
TriumeqAbacavir/Dolutegravir/Lamivudi12$41,070
OdefseyEmtricitab/Rilpiviri/Tenof Ala11$38,578
Daptomycin18$11,889
ErtapenemErtapenem Sodium19$4,097
Vancomycin Hcl26$3,897
Cefazolin Sodium42$2,542
Cefadroxil48$2,021
Rifampin21$1,793
Ethambutol Hcl20$1,593
CeftriaxoneCeftriaxone Sodium21$943
Azithromycin24$552
Doxycycline Hyclate25$453
Ciprofloxacin Hcl14$297

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Insmed, Inc.Arikayce$371$279,77818 claims
GileadBiktarvy$376$160,17542 claims
Viiv Healthcare CompanyTriumeq$152$41,07012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 102 infectious disease providers in South Carolina.

Other infectious disease in Spartanburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →